Kent D. Stewart - Concepedia

Author

Kent D. Stewart

Also Known As

K D Stewart, K STEWART, K Stewart, K. D. STEWART, K. D. Stewart, K. Stewart, K.D. Stewart, KENT D. STEWART, KENT STEWART, Kent D. Stewart

138

Publications

5.2K

Citations

H-Index

107

Concepts

All Affiliations

Abbott Fund Abbott (United States)Abbott (United Kingdom)Australian National University

About

Kent D. Stewart is an author at Abbott Fund specializing in medicine, natural sciences, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	65	3.4K
2	Natural Sciences	29	47	2.4K
3	Biochemistry	26	42	2K
4	Engineering	4	4	143
5	Health Sciences	2	2	222

Kent D. Stewart

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease Hing L. Sham, Dale J. Kempf, Akhteruzammen Molla, Antimicrobial Agents and Chemotherapy	1998	468
Discovery of<i>N</i>-(4-(3-Amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N</i>‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor Yujia Dai, Kresna Hartandi, Zhiqin Ji, Journal of Medicinal Chemistry Compound 17PDrug TargetChemoprevention StrategyKinase InhibitorsPharmacotherapy	2007	180
In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor Alejandro Vicente‐Carrillo, Kent D. Stewart, Hing L. Sham, Journal of Virology Human RetrovirusResistant Hiv-1ImmunologyAntiviral ResponseMolecular Biology	1998	171
Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro Liangjun Lu, Kent D. Stewart, John T. Randolph, Antimicrobial Agents and Chemotherapy ImmunologyMolecular BiologyPathologyAntiviral DrugHcv Replicons	2004	164
Novel Transient Receptor Potential Vanilloid 1 Receptor Antagonists for the Treatment of Pain: Structure−Activity Relationships for Ureas with Quinoline, Isoquinoline, Quinazoline, Phthalazine, Quinoxaline, and Cinnoline Moieties Arthur Gomtsyan, Erol K. Bayburt, Robert G. Schmidt, Journal of Medicinal Chemistry Pain MedicineImmunologyReceptor AntagonistsNeuropathic PainMolecular Pain	2005	163
Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors Yujia Dai, Yan Guo, Robin R. Frey, Journal of Medicinal Chemistry Drug TargetPharmacotherapyPharmaceutical ChemistryThienopyrimidine UreasTumor Biology	2005	152
Design, Synthesis, and Structural Analysis of Influenza Neuraminidase Inhibitors Containing Pyrrolidine Cores Gary T. Wang, Yuanwei Chen, Sheldon Wang, Journal of Medicinal Chemistry Combinatorial ChemistryEnzyme Active SiteMedicinal ChemistryBiochemistryNatural Sciences	2001	132
Influenza Neuraminidase Inhibitors: Structure-Based Design of a Novel Inhibitor Series Vincent S. Stoll, Kent D. Stewart, Clarence J. Maring, Biochemistry	2003	128
Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro Hongmei Mo, Liangjun Lu, Ron Pithawalla, Antimicrobial Agents and Chemotherapy Viral ReplicationHepatitis C VirusViral HepatitisCompounds A-782759Antiviral Therapy	2005	120
Pharmacological and Functional Comparison of the Polo-like Kinase Family: Insight into Inhibitor and Substrate Specificity Eric F. Johnson, Kent D. Stewart, Keith W. Woods, Biochemistry Polo-like Kinase FamilyMolecular BiologyMolecular PharmacologySignaling PathwayReceptor Tyrosine Kinase	2007	115

Page 1